Experiment Protocol Biomedical Engineer in Spain Valencia –Free Word Template Download with AI

Principal Investigator: Lead Biomedical Engineer
Regulatory Framework: Spanish Law 14/2007 on Biomedical Research; EU Clinical Trials Regulation (EU) No 536/2014.

This Experiment Protocol outlines the methodology for the validation of a novel wearable biosensor designed for continuous cardiac rhythm monitoring. The research is conducted by a team of Biomedical Engineers at a leading research facility in Valencia, Spain. Valencia has emerged as a significant hub for health technology in Europe, offering a unique convergence of clinical expertise and engineering innovation. This study aims to bridge the gap between theoretical engineering models and practical clinical application within the Spanish healthcare context.

The primary objective is to assess the accuracy, reliability, and user comfort of the device compared to standard electrocardiogram (ECG) equipment used in Spanish hospitals. As a Biomedical Engineer, the investigator is responsible for ensuring that the device meets rigorous safety standards and technical specifications before it can be considered for broader clinical use.

The specific objectives of this experiment are as follows:

• To validate the signal fidelity of the wearable biosensor against a clinical-grade Holter monitor.
• To evaluate the device's performance under various environmental conditions typical of Valencia, including high humidity and temperature variations.
• To assess the ergonomic design and skin compatibility of the sensor over a 48-hour period.
• To ensure compliance with the General Data Protection Regulation (GDPR) regarding the handling of sensitive health data.

3.1 Study Design

This is a prospective, single-center, observational study. The experiment will take place at the clinical engineering laboratory in Valencia. The study design adheres to the ethical principles outlined in the Declaration of Helsinki and the specific regulations enforced by the Spanish Agency of Medicines and Medical Devices (AEMPS).

3.2 Participants

The study will recruit 30 healthy adult volunteers aged between 25 and 65. Recruitment will be conducted locally in Valencia. Inclusion criteria require participants to have no known history of cardiac arrhythmias. Exclusion criteria include skin conditions that might interfere with sensor adhesion or a history of adverse reactions to adhesive materials. All participants must provide informed consent in accordance with Spanish legal requirements.

3.3 Equipment

The experimental setup involves the following equipment:

• Test Device: Prototype Wearable Biosensor (Model X-200).
• Reference Standard: Clinical-grade 12-lead ECG machine and Holter monitor.
• Data Acquisition System: High-resolution digital signal processing unit.
• Environmental Controls: Sensors to monitor ambient temperature and humidity.

The experiment will be conducted in three distinct phases over a period of two weeks.

Phase 1: Calibration and Baseline

Upon arrival at the Valencia facility, the Biomedical Engineer will calibrate all equipment. Participants will undergo a baseline ECG using the reference standard. The wearable biosensor will then be applied to the participant's chest. The engineer will verify signal quality and ensure proper adhesion. Participants will remain in a controlled environment for one hour to establish baseline data.

Phase 2: Dynamic Monitoring

Participants will be asked to perform a series of standardized physical activities, including walking, climbing stairs, and light jogging. This phase is designed to test the device's robustness against motion artifacts. Simultaneously, the reference Holter monitor will record data. The Biomedical Engineer will monitor the data stream in real-time to detect any signal loss or anomalies.

Phase 3: Long-term Wear and Environmental Stress

Participants will wear the device for 48 hours while going about their daily lives in Valencia. This phase tests the device's battery life, data transmission stability, and comfort. Given the climate of Valencia, special attention will be paid to the device's performance during outdoor activities in warm weather. Participants will keep a diary of any discomfort or device issues.

Data analysis will be performed by the Biomedical Engineering team using specialized software. The primary metric for success is the correlation coefficient between the wearable biosensor and the reference ECG. A correlation coefficient of greater than 0.95 will be considered acceptable. Statistical analysis will be conducted using standard methods, and results will be reported with 95% confidence intervals. Any discrepancies in data will be investigated to determine if they are due to technical failure or user error.

The safety of the participants is paramount. The protocol has been reviewed and approved by the Clinical Research Ethics Committee of the Hospital General Universitario de Valencia. In the event of any adverse events, such as skin irritation or device malfunction, the participant will be instructed to remove the device immediately and contact the research team. All personal data will be anonymized and stored on secure servers located within the European Union, ensuring full compliance with GDPR.

This Experiment Protocol provides a comprehensive framework for the evaluation of a new biomedical device. By conducting this research in Valencia, Spain, we leverage the region's advanced healthcare infrastructure and engineering expertise. The insights gained from this study will contribute to the development of safer, more effective wearable health technologies, ultimately benefiting patients across Spain and beyond. The role of the Biomedical Engineer is critical in ensuring that the technical aspects of the study are executed with precision and integrity.